Our results suggest that deletion of ITK during CAR-T cell production may be a useful strategy for the development of sustainable and functional CAR-T cell therapy, which will potentially benefit patients whose T cell functional quality is low, as well as those who suffer from tumor relapses. This evidence concerns the gene ITK and neoplasm.